How many days does targeted breast cancer treatment usually require hospitalization?

The specific number of days of hospitalization for breast cancer surgery is related to the treatment plan. Most breast cancers now use breast-conserving surgery or modified radical mastectomy. For example, if the patient's tumor is judged to be very small, less than two centimeters, it may be carcinoma in situ or very early invasive cancer before surgery, then only breast-conserving surgery is needed, no lymph node dissection is required, and the number of days of hospitalization is only about 3 to 5 days. If there is no abnormality in the complete examination on the day of admission, the targeted drug Herceptin can generally be used on the second day. If there is no special reaction after the injection, the patient can be discharged on the second day.

Can breast cancer patients eat Panax notoginseng?

Patients are encouraged to receive standardized treatment. The current relevant guidelines and standards mention the treatment of breast cancer. The main methods include chemotherapy, radiotherapy, molecular targeted drug therapy, endocrine drug therapy, surgery, and traditional Chinese medicine. Therefore, for people in this age group, breast color Doppler ultrasound and molybdenum target screening should be performed on time to try to detect the disease in its early stages. Early clinical treatment can often achieve better treatment results. Breast cancer patients can eat some Panax notoginseng powder appropriately.

Is chemotherapy necessary after radical mastectomy for breast cancer?

From the above materials, the diagnosis of breast cancer is clear, but no detailed whole body examination data is provided. If there is no problem elsewhere, the stage is early and the pathological type is good. It is recommended to perform 21 gene testing before deciding whether chemotherapy is needed. It is also necessary to combine the recovery of the patient's own condition to decide whether chemotherapy is needed. At the same time, it is necessary to judge whether further chemotherapy is needed based on the postoperative pathological results and the patient's own immune function. This requires a unified determination of whether chemotherapy is needed based on age, immunohistochemistry and pathology.